Trials / Completed
CompletedNCT05391022
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Constellation Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pelabresib | Pelabresib monohydrate tablets |
Timeline
- Start date
- 2021-07-20
- Primary completion
- 2023-03-08
- Completion
- 2024-02-29
- First posted
- 2022-05-25
- Last updated
- 2025-07-28
Locations
10 sites across 3 countries: United States, Georgia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05391022. Inclusion in this directory is not an endorsement.